Involvement of Caspase-3 Activity and Survivin Downregulation in Cinobufocini-Induced Apoptosis in A 549 Cells

Abstract

Cinobufocini injection is a preparation containing water-soluble components of the toad skin. The aim of the present study was to investigate the apoptosis of human lung adenocarcinoma cell line A 549 induced by cinobufocini. A 549 or HLF-1(human lung fibroblast) cells were treated with cinobufocini at different concentrations for 24 and 48 h, respectively. The proliferation of cells was detected with the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay. Morphology of cells was carried out with scanning electronic microscopy (SEM) and Hoechst 33258 staining. The apoptosis rate was examined by flow cytometry. The expression of survivin was examined with RT-PCR and Western blot assay. The caspase-3 and caspase-7 activities were detected with caspase colorimetric protease assay. We found that cinobufocini significantly inhibited tumor growth of A 549 cells in a dose- and time-dependent manner without damaging non-cancerous cells (HLF-1) and induced granular apoptotic bodies of A 549 cells. Next, cinobufocini increased the percentage of cells in G1 phase and decreased the percentage of cells in S phase in A 549 cells. Furthermore, cinobufocini downregulated the expression of survivin mRNA and protein. Finally, cinobufocini upregulated caspase-3 activity. We concluded that cinobufocini induces apoptosis of A 549 cells, which is associated with the decreasing expression of survivin mRNA and protein, increasing caspase-3 activity of A 549 cells.

Get full access to this article

View all access options for this article.

References

Velcheti V, Agovindan R. Insulin-like growth factor and lung cancer. J Thorac Oncol 1:607–610, 2006.

Katakami N, Sugiura T, Nogami T, Yamamoto H, Negoro S, Nakano T, Okamoto N, Takada Y, Kodama K, Ariyoshi Y. Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908. Lung Cancer 43:93–100, 2004.

Bepler G. Lung cancer: provoking new concepts, generating novel ideas, and rekinding enthusiasm. Cancer Control 10:275–276, 2003.

Krenn L, Kopp B. Bufadienolides from animal and plant sources. Phytochemistry 48:1–29, 1998.

Morishita S, Shoji M, Oguni Y, Ito C, Higuchi M, Sakanashi M. Pharmacological actions of “kyushin”, a drug containing toad venom: cardiotonic and arrhythmogenic effects, and excitatory effect on respiration. Am J Chin Med 20:245–256, 1992.

Cao YH, Luo HS. Clinical observation of cinobufacini injection used to treat advanced primary liver cancer. Zhong Guo Yi Xue Wen Zhai Lao Nian Yi Xue 1:8–10, 2007.

Wang Y, Li JM, Yang CM, Zhang L, Shen ZX. Study on apoptosis of NB4 cells induced by cinobufagin and its mechanism. Tumor 6:534–537, 2005.

Wall NR, O’Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 63:230–235, 2003.

Lu M, Strohecker A, Chen F, Kwan T, Bosman J, Jordan VC, Cryns VL. Asprin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels. Clin Cancer Res 14 (10):3168–3176, 2008.

10.

Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 269:30761–30764, 1994.

11.

Tormanen-Napankangas U, Soini Y, Kahlos K, Kinnula V, Paakko P. Expression of caspases-3, −6 and −8 and their relation to apoptosis in non-small cell lung carcinoma. Int J Cancer 93:192–198, 2001.

12.

Kania J, Konturek SJ, Marlicz K, Hahn EG, Konturek PC. Expression of survivin and caspase-3 in gastric cancer. Dig Dis Sci 48:266–271, 2003.

13.

Zhao FL, Hu JH, Zhu XZ. Monocyte-mediated rotenone neurotoxicity towards human neuroblastoma SH-SY5Y: Role of Mitogen-activated protein kinases. Biol Pharm Bull 29:1372–1377, 2006.

14.

Sarela AI, Macadam RCA, Farmery SM, Markham AF, Guilou PJ. Expression of the antiapoptosis gene, Survivin, predicts death from recurrent colorectal carcinoma. Gut 46:645–650, 2000.

15.

Josha KS, Rathos MJ, Joshi RD, Sivakumar M, Mascarenhas M, Kamble S, Lal B, Sharma S. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276–00. Mol Cancer Ther 6(3): 918–925, 2007.

16.

Chen T, Yang I, Irby R, Shain KH, Wang HG, Quackenbush J, Coppola D, Cheng JQ, Yeatman TJ. Regulation of caspase expression and apoptosis by adenomatous polyposis coli. Cancer Res 63(15): 4368–4374, 2003.

17.

Ceruti S, Beltrami E, Matarrese P, Mazzola A, Cattabeni F, Malorni W, Abbracchio MP. A key role for caspase-2 and caspase-3 in the apoptosis induced by 2-chloro-2-deoxy-adenosine (cladribine) and 2-chloro-adenosine in human astrocytoma cells. Mol Pharmacol 63: 1437–1447, 2003.

18.

Miao GY, Lu QM, Zhang XL. Downregulation of survivin by RNAi inhibits growth of human gastric carcinoma cells. World J Gastroenterology 13:1170–1174, 2007.

19.

Westphal S, Kalthoff H. Apoptosis: targets in pancreatic cancer. Mol Cancer 2:6, 2003.

20.

Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, Cook BP, Dufault MR, Ferguson AT, Gao Y, He TC, Hermeking H, Hiraldo SK, Hwang PM, Lopez MA, LUderer HF, Mathews B, Petroziello JM, Polyak K, Zawel L, Kinzler KW. Analysis of human transcriptomes. Nat Genet 23:387–388, 1999.

21.

Shinohara ET, Gonzalez A, Massion PP, Chen H, Li M, Freyer AS, Olson SJ, Andersen JJ, Shyr Y, Carbone DP, Johnson DH, Hallahan DE, Lu B. Nuclear survivin predicts recurrence and poor survival in patients with resected non small cell lung carcinoma. Cancer 103:1685–1692, 2005.

22.

Rodel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rodel F. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radio-resistance factor. Int J Radiat Oncol Biol Phys 55:1341–1347, 2003.

23.

Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J, Price J, Chen J, Freeman M, Hallahan DE. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 64:2840–2845, 2004.

24.

Coma S, Noe V, Lavarino C, Adan J, Rivas M, Lopez-Matas M, Pagan R, Mitjans F, Vilaro S, Piulats J, Ciudad CJ. Use of siRNAs and antisense oligonucleotides against survivin RNA to inhibit steps leading to tumor angiogenesis. Oligonucleotides 14(2):100–113, 2004.

25.

Chiou SK, Jones MK, Tarnawski AS. Survivin- an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit 9:PI25–P129, 2003.

26.

Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JI, Chung CW, Jung YK, Oh BH. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and −7. Biochemistry 40:1117–1123, 2001.

27.

Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–584, 1998.

28.

Chen YC, Shen SC, Lee WR, Hsu FL, Lin HY, Ko CH, Tseng SW. Emodin induces apoptosis in human promyelokukemic HL-60 cells accompanied by activation of caspase-3 cascade but independent of reactive oxygen species production. Biochem Pharmacol 64(12):1713–1724, 2002.

29.

Chiu CC, Lin CHMY, Fang K. Etoposide (VP-16) sensitizes p53-deficient human non-small cell lung cancer cells to caspase-7-mediated apoptosis. Apoptosis 10:643–650, 2005.

30.

Su YH, Huang XQ, Zhang DZ, Zhang YN, Xie JM, Ling CQ. HPLC separation and determination of bufadienolide in cinobufacini injection. Chinese Traditional Patent Medicine 25(1):25–27, 2003

31.

Su YH, Yin XC, Xie JM, Gao B, Ling CQ. Inhibition effects of three kinds of bufotoxins on human SMMC-7721 and BEL-7402 hepatoma cells line. Acad J Sec Mil Med Univ 24(4):393–395, 2003.

32.

Yu CH, Kan SF, Pu HF, Jea Chien E, Wang PS. Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells. Cancer Sci 99(12):2467–2476, 2008.